

DAFTAR PUSTAKA

1. Patterson JW, Hosler GA. Basal cell carcinoma; Weedon's skin pathology. 5th edition. Virginia: Elsevier; 2021. 848-857p.
2. Zhang W, Zeng W, Jiang A, He Z, Shen X, Dong X, et al. Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019. *Cancer Med.* 2021;10(14):4905–22.
3. Elder DE, Massi D, Scolyer RA, Willemze R. Basal cell carcinoma. WHO Classification of Skin Tumours. 2018.26-38p
4. Rifani L, Riesye A, Supri Iriyanti H. Jalur Pensinyalan Hedgehog pada Karsinoma Sel Basal. *Pratista Patologi.* 2019;6(2).
5. Bakshi A, Chaudhary SC, Rana M, Elmets CA, Athar M. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. *Mol Carcinog.* 2017;56(12):2543–57.
6. Moisejenko-Golubovica J, Volkov O, Ivanova A, Groma V. Analysis of the occurrence and distribution of primary and recurrent basal cell carcinoma of head and neck coupled to the assessment of tumor microenvironment and Sonic hedgehog signaling. *Rom J Morphol Embryol.* 2020;61(3):821–31.
7. Bisceglia M, Panniello G, Galliani CA, Centola M, D'Errico MM, Minenna E, et al. Metastatic Basal Cell Carcinoma of the Skin: A Comprehensive Literature Review, including Advances in Molecular Therapeutics. *Adv Anat Pathol.* 2020;27(5):331–53.
8. Josh F, Mappiwali A, Sukamto TH. Evaluasi Kasus Karsinoma Sel Basal di Makassar Periode Januari 2017 sampai Desember 201. *J Rekonstruksi dan Estetik.* 2021;6(2):56.
9. Clinical N, Guidelines P, Guidelines N. NCCN Guidelines Version 1.2018 Panel Members Basal Cell Skin Cancer. *Natl Compr Cancer Netw.* 2018;
10. Toha SS, Rahman A, Mochtar M, Julianto I, Dharmawan N, Mawardi P, et al. Kejadian Karsinoma Sel Basal di RSUD Dr . Moewardi Surakarta Berdasarkan Subtipe Histopatologi menurut Jenis Kelamin, Usia, Lokasi Anatomi, dan Diameter Tumor. *CDK-275.* 2019;46(4):256–60.
11. François Kuonen^{1, 2,*}, Isabelle Surbeck¹, Kavita Y. Sarin², Monique Dontenwill³, Curzio Ruegg⁴, Michel Gilliet¹, Anthony E. Oro^{2,†} and OG. Tgf-B, Fibronectin and Integrin A5B1 Promote Invasion in Basal Cell Carcinoma. *J Invest Dermatol.* 2016;5(6):1–8.
12. David EE, Rosallie E, Misha R, George EM, I.Rubin A. Basal Cell Carcinoma. *Lever's histopathology of the skin.* 11th ed. Philadelphia: Wolters kluwer; 2015. 1006-18p p.

13. Yelitha S, Agus S, Yenny SW, Kedokteran F, Andalas U. Hubungan Ekspresi Ki-67 dan Tipe Stroma Peritumoral dengan Varian Histopatologik Karsinoma Sel Basal. *Maj Patol.* 2018;27(2):30–7.
14. Duman N, Korkmaz NŞ, Erol Z. Host immune responses and peritumoral stromal reactions in different basal cell carcinoma subtypes: Histopathological comparison of basosquamous carcinoma and high-risk and low-risk basal cell carcinoma subtypes. *Turkish J Med Sci.* 2016;46(1):28–34.
15. Kaur P, Mulvaney M, Andrew Carlson J. Basal cell carcinoma progression correlates with host immune response and stromal alterations: A histologic analysis. *Am J Dermatopathol.* 2006;28(4):293–307.
16. McCarthy JB, El-Ashry D, Turley EA. Hyaluronan, cancer-associated fibroblasts and the tumor microenvironment in malignant progression. *Front Cell Dev Biol.* 2018;6(MAY):1–13.
17. Omland SH, Wettergren EE, Mourier T, Hansen AJ, Asplund M, Mollerup S, et al. Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin. *BMC Cancer.* 2017;17(1):1–9.
18. Saini H, Rahmani Eliato K, Silva C, Allam M, Mouneimne G, Ros R, et al. The Role of Desmoplasia and Stromal Fibroblasts on Anti-cancer Drug Resistance in a Microengineered Tumor Model. *Cell Mol Bioeng.* 2018;11(5):419–33.
19. Omland SH, Hamrouni A, Gniadecki R. High diversity of the T-cell receptor repertoire of tumor-infiltrating lymphocytes in basal cell carcinoma. *Exp Dermatol.* 2017;26(5):454–6.
20. Shin N, Mo Son G, Shin DH, Kwon MS, Park BS, Kim HS, et al. Cancer-associated fibroblasts and desmoplastic reactions related to cancer invasiveness in patients with colorectal cancer. *Ann Coloproctol.* 2019;35(1):36–46.
21. Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. *Biochem J.* 2012;441(2):541–52.
22. Ueno H, Jones AM, Wilkinson KH, Jass JR, Talbot IC. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. *Gut.* 2004;53(4):581–6.
23. Ueno H, Ishiguro M, Nakatani E, Ishikawa T, Uetake H, Murotani K, et al. Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study. *Br J Cancer.* 2021;124(6):1088–97. Available from: <http://dx.doi.org/10.1038/s41416-020-01222-8>
24. Yanai H, Yoshikawa K, Ishida M, Tsuta K, Sekimoto M, Sugie T. Presence

- of myxoid stromal change and fibrotic focus in pathological examination are prognostic factors of triple-negative breast cancer: Results from a retrospective single-center study. *PLoS One*. 2021.;1–17p. Available from: <http://dx.doi.org/10.1371/journal.pone.0245725>
25. Tahkola K, Ahtiainen M, Mecklin JP, Kellokumpu I, Laukkanen J, Tammi M, et al. Stromal hyaluronan accumulation is associated with low immune response and poor prognosis in pancreatic cancer. *Sci Rep* [Internet]. 2021;11(1):1–9. Available from: <https://doi.org/10.1038/s41598-021-91796-x>
 26. Sasaki K, Sugai T, Ishida K, Osakabe M, Amano H, Kimura H, et al. Analysis of cancer-associated fibroblasts and the epithelial-mesenchymal transition in cutaneous basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. *Hum Pathol* [Internet]. 2018;79:1–8. Available from: <https://doi.org/10.1016/j.humpath.2018.03.006>
 27. Lacina L, Smetana K, Dvořánková B, Pytlík R, Kideryová L, Kučerová L, et al. Stromal fibroblasts from basal cell carcinoma affect phenotype of normal keratinocytes. *Br J Dermatol*. 2007;156(5):819–29.
 28. Mujić M. The role of the Hedgehog signaling pathway in cancer: A comprehensive review. *Bosn J Basic Med Sci*. 2018;9(3):173.
 29. Fania L, Didona D, Di Pietro FR, Verkhovskaia S, Morese R, Paolino G, et al. Basal cell carcinoma: From pathophysiology to novel therapeutic approaches. *Biomedicines*. 2021;9(2):1–33.
 30. Tsujino T, Seshimo I, Yamamoto H, Chew YN, Ezumi K, Takemasa I, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. *Clin Cancer Res*. 2007;13(7):2082–90.
 31. Wang Z, Yang Q, Tan Y, Tang Y, Ye J, Yuan B, et al. Cancer-Associated Fibroblasts Suppress Cancer Development: The Other Side of the Coin. *Front Cell Dev Biol*. 2021;1–12p.
 32. Kalluri R. The biology and function of fibroblasts in cancer. *Nat Rev Cancer* [Internet]. 2016;16(9):582–98. Available from: <http://dx.doi.org/10.1038/nrc.2016.73>
 33. Joshi RS, Kanugula SS, Sudhir S, Pereira MP, Jain S, Aghi MK. The role of cancer-associated fibroblasts in tumor progression. *Cancers (Basel)*. 2021;13(6):1–27.
 34. Han C, Liu T, Yin R. Biomarkers for cancer-associated fibroblasts. *BMC*. 2020;1–8.
 35. Vokurka M, Lacina L, Brábek J, Kolář M, Ng YZ, Smetana K. Cancer-Associated Fibroblasts Influence the Biological Properties of Malignant Tumours via Paracrine Secretion and Exosome Production. *Int J Mol Sci*. 2022;23(2).
 36. Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of

- definitions: Cancer-associated fibroblasts and their markers. *Int J Cancer*. 2020;146(4):895–905.
37. Sălan AI, Mărășescu PC, Camen A, Ciucă EM, Matei M, Florescu AM, et al. The prognostic value of CXCR4, α -SMA and WASL in upper lip basal cell carcinomas. *Rom J Morphol Embryol*. 2018;59(3):839–49.
 38. Iwulska K, Wszyńska-pawelec G, Zapaa J, Kosowski B. Differences in actin expression between primary and recurrent facial basal cell carcinomas as a prognostic factor of local recurrence. *Adv Dermatol Allergol* 2021; 490–497 DOI: <https://doi.org/10.5114/ada.2021.107935>
 39. Sunjaya AP, Sunjaya AF, Tan ST. The Use of BEREPA Immunohistochemistry Staining for Detection of Basal Cell Carcinoma. *J Skin Cancer*. 2017;2017.
 40. Tan ST. Penggunaan Uji Imunohistokimia BerEP4 sebagai Gold Standard Deteksi Karsinoma Sel Basal. *Indones J Cancer*. 2016;10(3):79.
 41. Dasgeb B, Mohammadi TM, Mehregan DR. Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma. *Biomark Cancer*. 2013;5:BIC.S11856.
 42. Fagotto F, Aslemarz A. EpCAM cellular functions in adhesion and migration, and potential impact on invasion: A critical review. *Biochim Biophys Acta - Rev Cancer* [Internet]. 2020;1874(2):188436. Available from: <https://doi.org/10.1016/j.bbcan.2020.188436>
 43. Brown TC, Sankpal N V., Gillanders WE. Functional implications of the dynamic regulation of EpCAM during epithelial-to-mesenchymal transition. *Biomolecules*. 2021;11(7):1–22.
 44. Gires O, Pan M, Schinke H, Canis M, Baeuerle PA. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? *Cancer Metastasis Rev*. 2020;39(3):969–87.
 45. Keller L, Werner S, Pantel K. Biology and clinical relevance of EpCAM. *Cell Stress*. 2019;3(6):165–80.
 46. Aiman Mohtar M, Syafruddin SE, Nasir SN, Yew LT. Revisiting the roles of pro-metastatic epcam in cancer. *Biomolecules*. 2020;10(2).
 47. Gaiser MR, Hirsch D, Gaiser T. Loss of epithelial cell adhesion molecule (EpCAM) in infiltrative basal cell carcinoma. *Int J Clin Exp Pathol*. 2018;11(1):406–1p
 48. Oh CC, Jin A, Koh WP. Trends of cutaneous basal cell carcinoma, squamous cell carcinoma, and melanoma among the Chinese, Malays, and Indians in Singapore from 1968-2016. *JAAD Int* [Internet]. 2021;4:39–45. Available from: <https://doi.org/10.1016/j.jdin.2021.05.006>
 49. Kiely JR, Patel AJK. A retrospective study of 694 Basal Cell Carcinoma excisions to quantify deep margin documentation and clearance compared

- to histological type and surgical margin. *J Plast Reconstr Aesthetic Surg.* 2019;72(11):1805–12p
50. Cai H, Sobue T, Kitamura T, Sawada N, Iwasaki M, Shimazu T, et al. Epidemiology of nonmelanoma skin cancer in Japan: Occupational type, lifestyle, and family history of cancer. *Cancer Sci.* 2020;111(11):4257–65.
 51. Cameron MC, Lee E, Hibler BP, Barker CA, Mori S, Cordova M, et al. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. *J Am Acad Dermatol [Internet].* 2019;80(2):303–17p
 52. Khalesi M, Waterhouse M, Whiteman DC, Johns R, Rosendahl C, Hackett T, et al. Comparison of PTCH1, COX-2, p53, and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk. *Int J Dermatol.* 2016;55(10):1096–105.
 53. Dika E, Scarfi F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, et al. Basal cell carcinoma: A comprehensive review. *Int J Mol Sci.* 2020;21(15):1–11.
 54. Kumar V, Abbas Abdul, Aster Jhon. Basal cell Carcinoma; Robbin and Cotrans Pathology basic of disease. 9th edition. Elsevier. 2015;1141-75 p.
 55. Coleman WB, Tsongalis GJ. Molecular pathology of skin cancer. Molecular pathology, The molecular of basic human pathology. 2nd edition. Academic press Elsevier. 2017;1122–34p.
 56. Hanna A, Shevde LA. Hedgehog signaling: Modulation of cancer properties and tumor microenvironment. *Mol Cancer [Internet].* 2016;15(1):1–14. Available from: <http://dx.doi.org/10.1186/s12943-016-0509-3>
 57. Tampa M, Georgescu SR, Mitran CI, Mitran MI, Matei C, Scheau C, et al. Recent advances in signaling pathways comprehension as carcinogenesis triggers in basal cell carcinoma. *J Clin Med.* 2020;9(9):1–17.
 58. Stanoszek LM, Wang GY, Harms PW. Histologic mimics of basal cell carcinoma. *Arch Pathol Lab Med.* 2017;141(11):1490–502.
 59. Chen SH, Zhang BY, Zhou B, Zhu CZ, Sun LQ, Feng YJ. Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche. *Am J Cancer Res.* 2019;9(1):1–21. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30755808> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6356921>
 60. Cerci FB, Kubo EM, Werner B. Comparison of basal cell carcinoma subtypes observed in preoperative biopsy and Mohs micrographic surgery. *An Bras Dermatol.* 2020;95(5):594–601p. Available from: <https://doi.org/10.1016/j.abd.2020.04.005>
 61. Kyrpychova L, Carr RA, Martinek P, Vanecek T, Perret R, Chottová-Dvořáková M, et al. Basal cell carcinoma with matrical differentiation: Clinicopathologic, immunohistochemical, and molecular

- biological study of 22 cases. *Am J Surg Pathol*. 2017;41(6):738–49.
62. Jakobiec FA, Zakka FR, Townsend DJ. Pleomorphic basal cell carcinoma of the eyelid with true ductular differentiation. *Graefe's Arch Clin Exp Ophthalmol*. 2012;250(3):451–4.
 63. Mercut R, Georgescu C, Popescu SM, Ciurea M, Scricciu M, Georgescu CC. Face Basosquamous Carcinoma, a Case Report. *Curr Heal Sci J*. 2014;40(4):277–80.
 64. Bourlidou E, Vahtsevanos K, Kyrgidis A, Tilaveridis I, Patsatsi A, Andreadis D, et al. Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre. *Eur J Dermatology*. 2019;29(5):490–9.
 65. Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. *Clin Exp Metastasis* [Internet]. 2019;36(3):171–98. Available from: <https://doi.org/10.1007/s10585-019-09966-1>
 66. Louault K, Li R. Cancer-Associated Fibroblasts: Understanding The Heterogeneity. *Cancers (Basel)*. MDPI. 2020;1–28.
 67. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. *Nat Rev Cancer* [Internet]. 2020;20(3):174–86. Available from: <http://dx.doi.org/10.1038/s41568-019-0238-1>
 68. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. *Am J Cancer Res* [Internet]. 2011;1(4):482–97. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21984967> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3186047>
 69. Osama R. Stromal Immunohistochemistry of the Smooth Muscle Actin Expression in Indolent Versus Aggressive Basal Cell Carcinoma S tromal Immunohistochemistry of the Smooth Muscle Actin Expression in Indolent Versus Aggressive Basal Cell Carcinoma. 2021;.
 70. Tai Y, Woods EL, Dally J, Kong D, Steadman R, Moseley R, et al. Myofibroblasts: Function, formation, and scope of molecular therapies for skin fibrosis. *Biomolecules*. 2021;11(8):1–27.
 71. Tan ST, Ghaznawie M, Heenan PJ, Dosan R. Basal cell carcinoma arises from interfollicular layer of epidermis. *J Oncol*. 2018;2018.
 72. Ansai SI, Takayama R, Kimura T, Kawana S. Ber-EP4 is a useful marker for follicular germinative cell differentiation of cutaneous epithelial neoplasms. *J Dermatol*. 2012;39(8):688–92.
 73. Sastroasmoro sudigdo, Ismael S. *Dasar-Dasar Metodologi Penelitian Klinis*. Sagung Seto. 2011;
 74. Mawardi P, Julianto I, Dharmawan N, Toh SS, Wirawan EP, Effendy I.

- The difference of angiogenic agent expression in basal cell carcinoma related to its aggressiveness. 2021;7:1–4.
75. Kratzsch D, Kendler M, Simon JC, Ziemer M. Basal cell carcinomas with perineural invasion: A clinical-therapeutic and histological challenge. *JDDG - J Ger Soc Dermatology*. 2016;14(2):173–5.
 76. Wardhana M, Darmaputra IGN, Adhilaksman IGN, Pramita NYM, Maharis RF, Puspawati MD, et al. Karakteristik kanker kulit di Rumah Sakit Umum Pusat Sanglah Denpasar tahun 2015-2018. *Intisari Sains Medis*. 2019;10(1):260–3.
 77. Oh CM, Cho H, Won YJ, Kong HJ, Roh YH, Jeong KH, et al. Nationwide trends in the incidence of melanoma and non-melanoma skin cancers from 1999 to 2014 in south korea. *Cancer Res Treat*. 2018;50(3):729–37.
 78. Marzuka AG, Book SE. Basal cell carcinoma: Pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. *Yale J Biol Med*. 2015;88(2):167–79.
 79. Peris K, Concetta M, Garbe C, Kaufmann R, Bastholt L, Basset N, et al. ScienceDirect Diagnosis and treatment of basal cell carcinoma : European consensus e based interdisciplinary guidelines. 2019;118:10–34.
 80. Mawardi P, Kalim H, Kalim KH, Fitri LE, Mintaroem K, Mudigdo A, et al. Mid-face location of primary basal cell carcinoma related to cancer aggressivity. *Asian Pacific J Trop Dis [Internet]*. 2016;6(8):650–3.
 81. Ghanadan A, Abbasi A, Rabet M, Abdollahi P, Abbasi MA. Characteristics of mixed type basal cell carcinoma in comparison to other BCC subtypes. *Indian J Dermatol*. 2014;59(1):56–9.
 82. Madison JH, Karl MH, Albert EZ. A systematic review of the incidence of basal cell carcinoma with perineural invasion:conventional pathology versus mohs micrographic surgery. *Arch Dermatological Res*. 2022;83.
 83. Adegboyega PA, Rodriguez S, McLarty J. Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma. *Hum Pathol [Internet]*. 2010;41(8):1128–37p
 84. Mercuț R, Ciurea ME, Mărgăritescu C, Popescu SM, Crăițoiu MM, Cotoi OS, et al. Expression of p53, D2-40 and α -smooth muscle actin in different histological subtypes of facial basal cell carcinoma. *Rom J Morphol Embryol*. 2014;55(2):263–72. acm,k
 85. Tampa M, Georgescu SR, Mitran MI, Mitran CI, Matei C, Caruntu A, et al. Current perspectives on the role of matrix metalloproteinases in the pathogenesis of basal cell carcinoma. *Biomolecules*. 2021;11(6):1–23.
 86. Chen J, Yang P, Xiao Y, Zhang Y, Liu J, Xie D, et al. Overexpression of α -sma-positive fibroblasts (CAFs) in nasopharyngeal Carcinoma predicts poor prognosis. *J Cancer*. 2017;8(18):3897–902.

87. Hodorogea A, Calinescu A, Antohe M, Balaban M, Nedelcu RI, Turcu G, et al. Epithelial-Mesenchymal Transition in Skin Cancers: A Review. *Anal Cell Pathol.Hindawi*. 2019



